Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

416 results about "Signal region" patented technology

Ultrasonic array probe signal acquisition component and preparation method thereof, and probe

The invention relates to the technical field of ultrasonic probes, in particular to an ultrasonic array probe signal acquisition component and a preparation method thereof, and a probe. The acquisition component provided by the invention comprises two or more probe array elements, each probe array element comprises a backing and a piezoelectric layer composed of two or more piezoelectric crystal plates; flangings of positive electrodes and negative electrodes of the two piezoelectric crystal plates are butted; the piezoelectric layer is divided into a lead region, a heat conduction region and a signal region; a backing is connected to the signal region, and the bottom of the backing is connected with the bottom of the backing of an adjacent probe array element; a heat dissipating piece is connected to the heat conduction region, and the heat dissipating piece is connected with the ground electrode of an outer cable; and a flexible circuit board is connected with the lead region, and the flexible circuit board is connected with the outer cable through the probe circuit board. According to the ultrasonic array probe signal acquisition component and the probe provided by invention, the problem of probe temperature rising is effectively solved, the send-receive capacity of signals is improved, probe functions of testing image resolution ratio and sharpness are improved, and the impact of the probe array element signal crosstalk to imaging sharpness is decreased.
Owner:EDAN INSTR

Digital switching amplifier

There is provided a digital switching amplifier capable of enhancing an S / N ratio at the time of a small signal output and reducing current consumption and electromagnetic interference (EMI). The digital switching amplifier according to the present invention is provided with an integrator 11 for integrating an input signal, quantizer 12 for quantizing the output signal of the integrator 11 with resolutions different for each of the predetermined signal regions, pulse width modulator 13 for performing pulse width modulation for each of signals quantized with different resolutions by the quantizer 12 using different proportionality coefficients, switching circuit 14 for providing the load 15 with electrical signals different in value for each of pulse-width modulated signals with different proportionality coefficients by the pulse width modulator 13 in response to the pulse-width modulated signal, and feedback circuit 17 for negatively feeding back the output of the quantizer 12 to the input of the integrator 11.
Owner:ASAHI KASEI ELECTRONICS CO LTD

Chimeric antigen acceptor of target BCMA (B cell maturation antigen) and application of chimeric antigen acceptor

The invention relates to a chimeric antigen acceptor of a target BCMA (B cell maturation antigen). The chimeric antigen acceptor comprises an extracellular identification region, a hinge region, a transmembrane region and an intracellular signal region, wherein the extracellular identification region has a BCMA resisting nanometer antibody sequence, and the BCMA resisting nanometer antibody sequence is a heavy-chain variable region sequence combining with BCMA and from alpacas. More specifically, the BCMA resisting nanometer antibody sequence is BCMA monoclonal antibody B1 or B65, the amino acid sequence of the B1 is as shown in SEQID NO.1, and the amino acid sequence of the B65 is as shown in SEQID NO.2. According to the chimeric antigen acceptor disclosed by the invention, compared witha traditional mouse-derived SCFV or humanized SCFV, the nanometer antibody from the alpacas is used, and has small molecule quantity and immunogenicity, the possibility that CAR-T cells prepared on the base of the nanometer antibody produce HAMA effects in vivo is smaller, the remaining time of the CAR-T cells in vivo can be longer, the CAR-T cells pass through BCMA protein on the surfaces of target tumor cells and activate signal channels at the downstream part of T cells, the capacity for killing tumor cells having BCMA target points is given to the T cells, and BCMA positive blood tumor canbe efficiently and specifically treated.
Owner:上海科棋药业科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products